IV Ketamine vs. Spravato (Esketamine): An Honest Comparison

Ketamine is a mixture of two mirror-image molecules. Esketamine — the medicine in Spravato — is one of those two molecules on its own, delivered as a nasal spray. They are related, but they are distinct products with distinct regulatory histories.

IV ketamine is FDA-approved as an anesthetic; when it is prescribed for depression or other psychiatric conditions, that use is off-label. Spravato went through the FDA review process and is FDA-approved for specific depression indications. Off-label prescribing is legal and common in medicine, but the distinction matters for evidence, oversight, and insurance — which is what the rest of this page covers.

Spravato's approval rests on clinical trials submitted to the FDA for its specific indications. IV ketamine has its own research base — including randomized controlled trials in treatment-resistant depression published in 2006 and 2013 — but those studies were not part of an FDA approval submission, so IV ketamine remains not FDA-approved for depression even though the research exists.

Both bodies of evidence have limits. Follow-up periods are often short, and neither medicine has been shown to work for everyone. When you read claims about either treatment, ask whether they come from an approval program, an independent trial, or marketing.

Spravato is available only through a restricted distribution program called REMS (Risk Evaluation and Mitigation Strategy). Patients self-administer the nasal spray in a certified healthcare setting and are monitored afterward — the program requires observation before anyone leaves, and patients cannot drive until the next day.

IV ketamine has no single national program like REMS; standards are set clinic by clinic. At a minimum, you should expect an in-person medical evaluation, an infusion administered and monitored by qualified clinicians, recovery observation, and the same no-driving rule. If a provider offers IV ketamine without those elements, that is a warning sign worth taking seriously.

Because Spravato is FDA-approved for specific depression indications, it may have insurance coverage pathways — including prior authorization processes — that IV ketamine often lacks. Coverage is never automatic: it depends on your plan, your diagnosis, and whether you meet the approved criteria. IV ketamine for psychiatric conditions is commonly paid out of pocket.

We do not publish dollar figures here because verified pricing belongs on our cost page, and any coverage question has to be checked against your specific plan. What we can say plainly: ask both the clinic and your insurer what is covered before you commit to either course of treatment.

Beyond regulation and cost, the day-to-day experience differs. Spravato is used together with an oral antidepressant under its label. IV ketamine is typically given as a short series of infusions over several weeks. Scheduling, clinic availability in the Tampa Bay area, your other medications, and your own preference between a nasal spray and an infusion are all legitimate parts of the decision.

We are not going to answer that here, and you should be cautious of anyone who answers it without knowing your history. The choice depends on your diagnosis, prior treatments, medical conditions, insurance situation, and preferences. It is a decision to make with clinicians who can review your records — including your own psychiatrist or primary care physician — rather than from a web page. What we can do is give you honest information in a consultation so that decision is well-informed.